share_log

Prime Medicine Analyst Ratings

Prime Medicine Analyst Ratings

Prime 医学分析师评级
Benzinga ·  2023/10/09 07:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/09/2023 103.86% BMO Capital → $19 Initiates Coverage On → Outperform
09/06/2023 114.59% JonesTrading → $20 Initiates Coverage On → Buy
08/14/2023 103.86% Morgan Stanley $21 → $19 Maintains Equal-Weight
07/31/2023 157.51% Guggenheim → $24 Initiates Coverage On → Buy
04/18/2023 93.13% Stifel → $18 Initiates Coverage On → Buy
01/24/2023 125.32% Morgan Stanley $23 → $21 Maintains Equal-Weight
11/14/2022 189.7% JP Morgan → $27 Initiates Coverage On → Overweight
11/14/2022 168.24% Jefferies → $25 Initiates Coverage On → Buy
11/14/2022 146.78% Morgan Stanley → $23 Initiates Coverage On → Equal-Weight
11/14/2022 136.05% Goldman Sachs → $22 Initiates Coverage On → Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
10/09/2023 103.86% 蒙特利尔银行资本 →$19 开始承保 →跑赢大盘
09/06/2023 114.59% Jones Trading →$20 开始承保 →购买
2023年08月14日 103.86% 摩根士丹利 $21→$19 维护 等重
07/31/2023 157.51% 古根海姆 →$24 开始承保 →购买
04/18/2023 93.13% Stifel →$18 开始承保 →购买
01/24/2023 125.32% 摩根士丹利 $23→$21 维护 等重
2022年11月14日 189.7% 摩根大通 →$27 开始承保 →超重
2022年11月14日 168.24% 杰富瑞 →$25 开始承保 →购买
2022年11月14日 146.78% 摩根士丹利 →$23 开始承保 →等重
2022年11月14日 136.05% 高盛 →$22 开始承保 →中性

What is the target price for Prime Medicine (PRME)?

Prime Medicine(PRME)的目标价格是多少？

The latest price target for Prime Medicine (NASDAQ: PRME) was reported by BMO Capital on October 9, 2023. The analyst firm set a price target for $19.00 expecting PRME to rise to within 12 months (a possible 103.86% upside). 10 analyst firms have reported ratings in the last year.

蒙特利尔银行资本公司于2023年10月9日报道了Prime Medicine(纳斯达克代码：PRME)的最新目标价。这家分析公司将目标价定为19美元，预计PRME将在12个月内上涨(可能上涨103.86%)。去年有10家分析公司公布了评级。

What is the most recent analyst rating for Prime Medicine (PRME)?

最新分析师对Prime Medicine(PRME)的评级是多少？

The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by BMO Capital, and Prime Medicine initiated their outperform rating.

蒙特利尔银行资本对优质医药(纳斯达克代码：PRME)的最新分析师评级是由蒙特利尔银行资本提供的，优质医药发起了其表现优于大盘的评级。

When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?

Prime Medicine(PRME)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on October 9, 2023 so you should expect the next rating to be made available sometime around October 9, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Prime Medicine的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Prime Medicine的上一次评级是在2023年10月9日提交的，所以你应该预计下一次评级将在2024年10月9日左右提供。

Is the Analyst Rating Prime Medicine (PRME) correct?

分析师对Prime Medicine(PRME)的评级正确吗？

While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $19.00. The current price Prime Medicine (PRME) is trading at is $9.32, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Prime Medicine(PRME)评级是以0.00美元至19.00美元的目标价启动的。Prime Medicine(PRME)目前的交易价格为9.32美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发